Medytox said it recorded sales of 61.6 billion won ($44.3 million), operating profit of 6.3 billion won, and net profit of 8.2 billion won in the second quarter of 2025, with higher overseas demand for its botulinum toxin products and reduced legal costs helping lift profitability.

While revenue fell 3.6 percent from the previous quarter, operating profit and net profit rose 15.4 percent and 144.5 percent, respectively.

Compared to the same period last year, sales, operating profit, and net profit were down 5.2 percent, 55.9 percent, and 27.8 percent, respectively.

The company marked its first time surpassing 60 billion won in sales for two consecutive quarters, supported by steady performance in its core botulinum toxin and dermal filler businesses.

Botulinum toxin exports grew 17 percent quarter-on-quarter and 16 percent year-on-year, underscoring continued overseas demand. Medytox said it plans to accelerate the overseas registration of its botulinum toxin brand “Newlux” in the second half of the year to drive further revenue growth.

The company also noted that selling and administrative expenses have begun to decline as some legal disputes have been resolved, a trend expected to positively impact future profitability.

“With Newlux already well-recognized in the domestic market, its full-scale expansion abroad in the second half will help fuel sales growth,” a Medytox official said. “We will also focus on completing key ongoing projects, including filing for U.S. FDA approval of our next-generation liquid toxin MT10109L and obtaining market authorization for ‘MT921,’ the world’s first cholic acid-based fat-dissolving injectable.”